maasol -
ge healthcare as - albumin humant serum makroaggregater ad tc-99m makroalbumin - pulver til injeksjonsvæske, suspensjon
nanocoll -
ge healthcare as - albumin humant kolloidale partikler ad tc-99m albumin nanokolloid - pulver til injeksjonsvæske, suspensjon
ovitrelle 250 mikrog
2care4 aps - koriongonadotropin alfa - injeksjonsvæske, oppløsning - 250 mikrog
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
sodium iodide [131i] diagnostic capsules ge healthcare 3.7 mbq
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq
theracap 131tm -
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard
bylvay
albireo - odevixibat - cholestasis, intrahepatic - galle- og leverterapi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 og 5.
evkeeza
ultragenyx germany gmbh - evinacumab - hyperkolesterolemi - lipid modifiserende midler - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).